Biotricity Reports Financial Results for Fiscal 2023 First Quarter
Biotricity Reports Financial Results for Fiscal 2023 First Quarter
REDWOOD CITY, CA / ACCESSWIRE / August 15, 2022 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a medical diagnostic and consumer healthcare technology company, today announced its financial results for its fiscal 2023 first quarter ended June 30, 2022.
加利福尼亚州雷德伍德城/ACCESSWIRE/2022年8月15日/医疗诊断和消费者保健技术公司Biotricity Inc.(纳斯达克代码：BTCY)(以下简称“公司”)今天公布了截至2022年6月30日的2023财年第一季度财务业绩。
Dr. Waqaas Al-Siddiq, Founder & CEO of Biotricity, commented, "We are pleased with our year-over-year revenue growth and ability to maintain gross margins at 60% as we begin to roll out our new Biotres and Bioheart products lines through our established network. Both new product offerings will complement the existing platform we have built through Bioflux to make the Biotricity ecosystem an all-in-one go-to solution for cardiologists. Additionally, because Biotres is a higher volume wireless wearable cardiac monitoring device as compared to Bioflux, we expect to expand our distribution to include channels such as Hospital Networks or Integrated Delivery Networks."
Biotricity创始人兼首席执行官Waqaas Al-Siddiq博士表示：“随着我们开始通过我们已建立的网络推出新的Biotres和BioHeart产品线，我们对收入的同比增长和毛利率保持在60%的能力感到高兴。这两个新产品将补充我们通过BioFlux建立的现有平台，使Biotricity生态系统成为心脏病专家的一站式解决方案。此外，由于Biotres是一种与Bioflow相比容量更大的无线可穿戴心脏监测设备，我们预计将扩大我们的分销范围，包括医院网络或集成交付网络等渠道。”
Q1-FY23 Financial Highlights:
第一季度至23财年财务亮点：
- Revenue totaled $2.1 million.
- Gross profit totaled $1.2 million.
- Gross profit margins were 60% and consistent with the full year FY22.
- Net loss totaled $5 million or $0.098 per share; adjusted loss per share, a non- GAAP measure, was $0.085 per share after removing certain non-recurring expenses.
- 总收入为210万美元。
- 毛利润总计120万美元。
- 毛利率为60%，与22财年全年持平。
- 净亏损总计500万美元，或每股0.098美元；调整后的每股亏损(非公认会计准则衡量标准)在扣除某些非经常性费用后为每股0.085美元。
Operating Highlights for the FY22 to Date:
到目前为止，22财年的运营要点：
- After receiving FDA 510(k) clearance in January 2022, in April 2022, Biotricity officially launched wireless wearable holter patch device, Biotres, a revolutionary holter technology.
- Unveiled Biokit, a personal medical device kit for integration into the Biotricity ecosystem.
- Launched Bioheart, one of the first heart rhythm recorders and personal heart lifestyle solutions.
- Expanded our network to cover 29 states with over 2,000 physicians using our product.
- 在2022年1月获得FDA 510(K)批准后，2022年4月，Biotricity正式推出了无线可穿戴Holter贴片设备Biotres，这是一项革命性的Holter技术。
- 推出了Biokit，这是一款集成到Biotricity生态系统中的个人医疗设备套件。
- 推出了首批心脏节律记录仪和个人心脏生活方式解决方案之一BioHeart。
- 将我们的网络扩展到29个州，有超过2,000名医生使用我们的产品。
Full details of the Company's financial results will be filed with the SEC on Form 10-Q by visiting www.sec.gov.
公司财务业绩的全部细节将以10-Q表格的形式提交给美国证券交易委员会，网址为www.sec.gov。
Financial Results Conference Call
财务业绩电话会议
Management will host a conference call on Monday, August 15, 2022 at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter and provide a business update. Additional details are available under the Investor Relations section of the Company's website:
管理层将于2022年8月15日(星期一)下午4：30主持电话会议。ET讨论其2023财年第一季度的财务业绩，并提供业务最新情况。欲了解更多详情，请登录公司网站投资者关系栏目：
Event: |
Biotricity Fiscal First Quarter 2023 Financial Results Conference Call |
Date: |
Monday, August 15, 2022 |
Time: |
4:30 p.m. Eastern Time |
Live Call: |
1-888-220-8451 (U.S. Toll-Free) or 1-646-828-8193 (International) |
Webcast: |
活动： |
Biotricity财年2023年第一季度财务业绩电话会议 |
日期： |
2022年8月15日(星期一) |
时间： |
下午4：30东部时间 |
现场通话： |
1-888-220-8451(美国免费)或1-646-828-8193(国际) |
网络直播： |
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 29, 2022 and can be accessed by dialing +1-844-512-2921 (U.S. Toll Free) or +1-412-317-6671 (International) and entering replay pin number: 2688378.
对于不能参加电话会议的感兴趣的个人，在2022年8月29日之前可以拨入电话重播，可以通过拨打+1-844-512-2921(美国免费)或+1-412-317-6671(国际)并输入重播密码：2688378来收听。
About Biotricity:
关于Biotricity公司：
Biotricity is reforming the healthcare market by bridging the gap in remote monitoring and chronic care management. Doctors and patients trust Biotricity's unparalleled standard for preventive & personal care, including diagnostic and post-diagnostic solutions for chronic conditions. The company develops comprehensive remote health monitoring solutions for the medical and consumer markets. To learn more, visit .
Biotricity正在通过弥合远程监测和慢性护理管理方面的差距来改革医疗保健市场。医生和患者信赖Biotricity无与伦比的预防和个人护理标准，包括针对慢性病的诊断和诊断后解决方案。该公司为医疗和消费市场开发全面的远程健康监测解决方案。要了解更多信息，请访问。
Important Cautions Regarding Forward Looking Statements:
有关前瞻性陈述的重要警告：
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "should," "would," "will," "could," "scheduled," "expect," "anticipate," "estimate," "believe," "intend," "seek," "project," or "goal" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements may include, without limitation, statements regarding (i) the plans, objectives and goals of management for future operations, including plans, objectives or goals relating to the design, development and commercialization of Bioflux or any of the Company's other proposed products or services, (ii) a projection of income (including income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial items, (iii) the Company's future financial performance, (iv) the regulatory regime in which the Company operates or intends to operate and (v) the assumptions underlying or relating to any statement described in points (i), (ii), (iii) or (iv) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the significant length of time and resources associated with the development of its products and related insufficient cash flows and resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies. These and other factors are identified and described in more detail in the Company's filings with the SEC. There cannot be any assurance that the Company will ever become profitable. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release.
本新闻稿中包含的任何不描述历史事实的陈述都可能构成前瞻性陈述。前瞻性陈述涉及假设并描述我们未来的计划、战略和预期，通常可以通过使用“可能”、“应该”、“将”、“将”、“可能”、“预定”、“预期”、“预期”、“估计”、“相信”、“打算”、“寻求”、“项目”或“目标”或这些词语或类似术语的其他变体来识别。前瞻性陈述可能包括但不限于：(I)未来经营的计划、目标和目标，包括与BioFlux或公司任何其他拟议产品或服务的设计、开发和商业化有关的计划、目标或目标；(Ii)收入(包括收益/亏损)、每股收益(包括收益/亏损)、资本支出、股息、资本结构或其他财务项目的预测；(Iii)公司未来的财务业绩，(Iv)本公司营运或拟营运的监管制度及(V)上文第(I)、(Ii)、(Iii)或(Iv)点所述任何陈述所依据或有关的假设。此类前瞻性陈述不是为了预测或保证实际结果、业绩、事件或情况，也可能无法实现，因为它们是基于公司目前的预测、计划、目标、信念、预期、估计和假设，受到许多风险、不确定因素和其他影响的影响, 其中许多是公司无法控制的。由于这些风险和不确定性，某些事件和情况的实际结果和时间可能与前瞻性陈述中描述的大不相同。可能影响或导致前瞻性陈述不准确或导致实际结果与预期或预期结果大不相同的因素可能包括但不限于，公司无法获得额外融资，与其产品开发相关的大量时间和资源，以及相关的现金流不足和导致的流动性不足，公司无法扩大公司业务，政府对医疗器械和保健行业的重大监管，产品缺乏多样性，现有或加剧的竞争，仲裁和诉讼的结果，股票波动和流动性不足，以及公司未能执行公司的业务计划或战略。这些因素和其他因素在该公司提交给美国证券交易委员会的文件中得到了更详细的识别和描述。不能保证该公司将永远盈利。公司没有义务更新任何前瞻性陈述，以反映本新闻稿发布之日之后可能发生的任何事件或情况。
Use of Non-GAAP Information
非公认会计原则信息的使用
In addition to the unaudited results presented in accordance with generally accepted accounting principles, or GAAP in this press release, Biotricity presents adjusted net loss, which is a non-GAAP financial measure. Adjusted net loss is determined by deducting one-time derivative fair value and accretion expenses from net loss attributable to common shareholders. Our definition of adjusted net loss may not be comparable to the definitions of similarly titled measures used by other companies. We believe that this non-GAAP financial measure, viewed in addition to and not in lieu of its reported GAAP results, provides useful information to investors by providing a more focused measure of operating results. This metric is used as part of the Company's internal reporting to evaluate its operations and the performance of senior management.
除了根据公认会计原则或本新闻稿中的GAAP公布的未经审计的结果外，Biotricity还公布了调整后的净亏损，这是一种非GAAP财务衡量标准。调整后净亏损由普通股股东应占净亏损减去一次性衍生公允价值和增值费用确定。我们对调整后净亏损的定义可能不能与其他公司使用的类似标题衡量标准的定义相比较。我们认为，这一非GAAP财务指标是对其报告的GAAP结果的补充，而不是替代它，通过提供更有针对性的经营业绩指标，为投资者提供了有用的信息。这一指标被用作公司内部报告的一部分，以评估其运营和高级管理层的业绩。
The following reconciliation calculates the adjusted loss per share:
以下对帐计算调整后的每股亏损：
|
3 months ended June 30, 2022 |
||||
| $ | ||||
Net loss attributable to common stockholders |
(5,024,389 | ) | ||
Add: |
||||
Provision for income taxes |
- | |||
Interest expense |
388,388 | |||
Depreciation expense |
1,488 | |||
EBITDA |
(4,634,512 | ) | ||
Add (Less) |
||||
Other (income) expense related to convertible note conversion |
50,908 | |||
Fair value change on derivative liabilities |
198,224 | |||
Adjusted EBITDA |
(4,385,381 | ) | ||
Weighted average number of common shares outstanding |
51,440,944 | |||
Adjusted Loss per Share, Basic and Diluted |
(0.085 | ) | ||
|
3个月 告一段落 2022年6月30日 |
||||
| $ | ||||
普通股股东应占净亏损 |
(5,024,389 | ) | ||
添加： |
||||
所得税拨备 |
- | |||
利息支出 |
388,388 | |||
折旧费用 |
1,488 | |||
EBITDA |
(4,634,512 | ) | ||
加(减) |
||||
与可转换票据转换相关的其他(收益)费用 |
50,908 | |||
衍生负债的公允价值变动 |
198,224 | |||
调整后的EBITDA |
(4,385,381 | ) | ||
已发行普通股加权平均数 |
51,440,944 | |||
调整后每股基本亏损和稀释后每股亏损 |
(0.085 | ) | ||
Contacts:
联系人：
Investor Relations:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
investors@biotricity.com
投资者关系：
KCSA战略传播
瓦尔特·平托或杰克·珀金斯
(212) 896-1254
邮箱：Investors@Biotrity.com
Media Relations:
媒体关系：
Erica Fiorini, Russo Partners
(212) 845-4253
Erica.Fiorini@russopartnersllc.com
埃里卡·菲奥里尼，Russo Partners
(212) 845-4253
邮箱：Erica.Fiorini@russopartnersllc.com
BIOTRICITY INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS AT JUNE 30, 2022 (unaudited) AND MARCH 31, 2022 (audited)
(Expressed in US Dollars)
BIOTRICITY Inc.
简明合并资产负债表
截至2022年6月30日(未经审计)和2022年3月31日(已审计)
(以美元表示)
| As at June 30, 2022 | As at March 31, 2022 | |||||||
| $ | $ | |||||||
CURRENT ASSETS |
||||||||
Cash |
7,207,974 | 12,066,929 | ||||||
Accounts receivable, net |
1,826,920 | 2,006,678 | ||||||
Inventory |
1,431,054 | 842,924 | ||||||
Deposits and other receivables |
380,592 | 406,280 | ||||||
Total current assets |
10,846,540 | 15,322,811 | ||||||
Deposits |
85,000 | 85,000 | ||||||
Long-term accounts receivable |
- | - | ||||||
Property and equipment |
25,970 | 27,459 | ||||||
Operating right-of-use lease asset [Note 10] |
1,192,169 | 1,242,700 | ||||||
TOTAL ASSETS |
12,149,679 | 16,677,970 | ||||||
CURRENT LIABILITIES |
||||||||
Accounts payable and accrued liabilities [Note 4]
|
2,701,077 | 2,595,747 | ||||||
Convertible promissory notes and short term loans [Note 5]
|
1,238,000 | 1,540,000 | ||||||
Derivative liabilities [Note 8] |
419,332 | 520,747 | ||||||
Operating lease liability [Note 10] |
219,033 | 210,320 | ||||||
Total current liabilities |
4,577,442 | 4,866,814 | ||||||
Federally guaranteed loans [Note 7] |
870,800 | 870,800 | ||||||
Term loan [Note 6] |
11,662,742 | 11,612,672 | ||||||
Derivative liabilities [Note 8] |
537,318 | 352,402 | ||||||
Operating lease liability [Note 10] |
1,061,795 | 1,120,018 | ||||||
TOTAL LIABILITIES |
18,710,097 | 18,822,706 | ||||||
STOCKHOLDERS' EQUITY (DEFICIENCY) |
||||||||
Preferred stock, $0.001 par value, 10,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 1 share issued and outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] |
1 | 1 | ||||||
Preferred stock, $0.001 par value, 20,000 authorized as at June 30, 2022 and March 31, 2022, respectively, 6,872 and 7,201 preferred shares issued and outstanding as at June 30, 2022 and as at March 31, 2022, respectively [Note 9] |
8 | 7 | ||||||
Preferred stock |
1 | 1 | ||||||
Common stock, $0.001 par value, 125,000,000 authorized as at June 30, 2022 and March 31, 2022, respectively. Issued and outstanding common shares: 50,219,034 and 49,810,322 as at June 30, 2022 and March 31, 2022, respectively, and exchangeable shares of 1,466,718 and 1,466,718 outstanding as at June 30, 2022 and March 31, 2022, respectively [Note 9] |
51,685 | 51,277 | ||||||
Shares to be issued 95,515 and 123,817 shares of common stock as at June 30, 2022 and March 31, 2022, respectively) [Note 9] |
72,299 | 102,299 | ||||||
Additional paid-in-capital |
91,912,772 | 91,507,478 | ||||||
Accumulated other comprehensive loss |
(535,653 | ) | (768,656 | ) | ||||
Accumulated deficit |
(98,061,531 | ) | (93,037,142 | ) | ||||
Total stockholders' equity (deficiency) |
(6,560,418 | ) | (2,144,736 | ) | ||||
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIENCY |
12,149,679 | 16,677,970 | ||||||
| 截至2022年6月30日 | 截至2022年3月31日 | |||||||
| $ | $ | |||||||
流动资产 |
||||||||
现金 |
7,207,974 | 12,066,929 | ||||||
应收账款净额 |
1,826,920 | 2,006,678 | ||||||
库存 |
1,431,054 | 842,924 | ||||||
押金和其他应收款 |
380,592 | 406,280 | ||||||
流动资产总额 |
10,846,540 | 15,322,811 | ||||||
存款 |
85,000 | 85,000 | ||||||
长期应收账款 |
- | - | ||||||
财产和设备 |
25,970 | 27,459 | ||||||
经营性使用权租赁资产[注10] |
1,192,169 | 1,242,700 | ||||||
总资产 |
12,149,679 | 16,677,970 | ||||||
流动负债 |
||||||||
应付账款和应计负债[注4]
|
2,701,077 | 2,595,747 | ||||||
可转换本票和短期贷款[注5]
|
1,238,000 | 1,540,000 | ||||||
衍生负债[注8] |
419,332 | 520,747 | ||||||
经营租赁负债[注10] |
219,033 | 210,320 | ||||||
流动负债总额 |
4,577,442 | 4,866,814 | ||||||
联邦担保贷款[注7] |
870,800 | 870,800 | ||||||
定期贷款[注6] |
11,662,742 | 11,612,672 | ||||||
衍生负债[注8] |
537,318 | 352,402 | ||||||
经营租赁负债[注10] |
1,061,795 | 1,120,018 | ||||||
总负债 |
18,710,097 | 18,822,706 | ||||||
股东权益(不足) |
||||||||
优先股，面值0.001美元，于2022年6月30日及2022年3月31日分别核准1,000,000股，分别于2022年6月30日及2022年3月31日发行及发行1股[注9] |
1 | 1 | ||||||
优先股，面值0.001美元，截至2022年6月30日和2022年3月31日分别为20,000股已发行优先股和已发行优先股分别为6,872股和7,201股[注9] |
8 | 7 | ||||||
优先股 |
1 | 1 | ||||||
普通股，面值0.001美元，截至2022年6月30日和2022年3月31日分别授权1.25亿股。已发行和已发行普通股：截至2022年6月30日和2022年3月31日分别为50,219,034股和49,810,322股，截至2022年6月30日和2022年3月31日分别为1,466,718股和1,466,718股可交换股份[注9] |
51,685 | 51,277 | ||||||
于2022年6月30日及2022年3月31日分别发行95,515股及123,817股普通股)[注9] |
72,299 | 102,299 | ||||||
追加实收资本 |
91,912,772 | 91,507,478 | ||||||
累计其他综合损失 |
(535,653 | ) | (768,656 | ) | ||||
累计赤字 |
(98,061,531 | ) | (93,037,142 | ) | ||||
股东权益合计(亏空) |
(6,560,418 | ) | (2,144,736 | ) | ||||
总负债与股东缺位 |
12,149,679 | 16,677,970 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
FOR THE THREE MONTHS ENDED JUNE 31, 2022 AND 2021 (unaudited)
(Expressed in US Dollars)
BIOTRICITY Inc.
简明合并经营报表和全面亏损
截至2022年6月31日和2021年6月31日的三个月(未经审计)
(以美元表示)
|
3 Months Ended June 30, 2022 |
3 Months Ended June 30, 2021 |
|||||||
| $ | $ | |||||||
REVENUE |
2,056,052 | 1,764,110 | ||||||
Cost of Revenue |
830,923 | 525,426 | ||||||
GROSS PROFIT |
1,225,129 | 1,238,684 | ||||||
EXPENSES |
||||||||
General and administrative expenses [Notes 8, 9 and 10]
|
4,881,003 | 3,652,203 | ||||||
Research and development expenses |
821,176 | 588,997 | ||||||
TOTAL OPERATING EXPENSES |
5,702,179 | 4,241,200 | ||||||
Other (income)/expense [Note 8] [Note 9] |
- | (8,782 | ) | |||||
Loss upon convertible promissory notes conversion |
50,908 | 28,215 | ||||||
Accretion and amortization expenses [Note 5] [Note 6] |
50,070 | 2,335,167 | ||||||
Change in fair value of derivative liabilities [Note 8] |
198,224 | 298,983 | ||||||
NET LOSS BEFORE INCOME TAXES |
(4,776,252 | ) | (5,656,099 | ) | ||||
Income taxes |
- | - | ||||||
NET LOSS BEFORE DIVIDENDS |
(4,776,252 | ) | (5,656,099 | ) | ||||
Less: Preferred Stock Dividends |
248,137 | 241,264 | ||||||
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS |
(5,024,389 | ) | 5,897,363 | |||||
Translation adjustment |
233,003 | 6,560 | ||||||
COMPREHENSIVE LOSS |
(4,791,386 | ) | (5,890,803 | ) | ||||
LOSS PER SHARE, BASIC AND DILUTED |
(0.098 | ) | (0.151 | ) | ||||
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING |
51,440,944 | 39,095,637 | ||||||
|
截至3个月 2022年6月30日 |
截至3个月 2021年6月30日 |
|||||||
| $ | $ | |||||||
收入 |
2,056,052 | 1,764,110 | ||||||
收入成本 |
830,923 | 525,426 | ||||||
毛利 |
1,225,129 | 1,238,684 | ||||||
费用 |
||||||||
一般和行政费用[附注8、9及10]
|
4,881,003 | 3,652,203 | ||||||
研发费用 |
821,176 | 588,997 | ||||||
总运营费用 |
5,702,179 | 4,241,200 | ||||||
其他(收入)/支出[注8][注9] |
- | (8,782 | ) | |||||
可转换本票兑换损失 |
50,908 | 28,215 | ||||||
累加和摊销费用[注5][注6] |
50,070 | 2,335,167 | ||||||
衍生负债的公允价值变动[注8] |
198,224 | 298,983 | ||||||
所得税前净亏损 |
(4,776,252 | ) | (5,656,099 | ) | ||||
所得税 |
- | - | ||||||
派发股息前净亏损 |
(4,776,252 | ) | (5,656,099 | ) | ||||
减去：优先股股息 |
248,137 | 241,264 | ||||||
普通股股东应占净亏损 |
(5,024,389 | ) | 5,897,363 | |||||
翻译调整 |
233,003 | 6,560 | ||||||
综合损失 |
(4,791,386 | ) | (5,890,803 | ) | ||||
每股基本亏损和稀释后每股亏损 |
(0.098 | ) | (0.151 | ) | ||||
已发行普通股加权平均数 |
51,440,944 | 39,095,637 | ||||||
BIOTRICITY INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE THREE MONTHS ENDED JUNE 30, 2022 AND 2021 (UNAUDITED)
(Expressed in US Dollars)
BIOTRICITY Inc.
简明合并现金流量表
截至2022年6月30日和2021年6月30日的三个月(未经审计)
(以美元表示)
| Three Months Ended June 30, 2022 | Three Months Ended June 30, 2021 | |||||||
| $ | $ | |||||||
CASH FLOWS FROM OPERATING ACTIVITIES |
||||||||
Net loss |
(4,776,252 | ) | (5,656,099 | ) | ||||
Adjustments to reconcile net loss to net cash used in operations |
||||||||
Stock based compensation |
149,190 | 155,851 | ||||||
Issuance of shares for services |
7,051 | - | ||||||
Issuance of warrants for services |
77,414 | 151,897 | ||||||
Accretion and amortization expenses |
- | 2,335,167 | ||||||
Change in fair value of derivative liabilities |
198,224 | 298,983 | ||||||
Loss on debt |
50,908 | 28,213 | ||||||
Property, plant and equipment depreciation |
1,488 | - | ||||||
Changes in operating assets and liabilities: |
||||||||
Accounts receivable, net |
179,758 | (401,818 | ) | |||||
Inventory |
(588,130 | ) | 92,694 | |||||
Deposits and other receivables |
(4,312 | ) | (86,221 | ) | ||||
Accounts payable and accrued liabilities |
416,047 | 399,937 | ||||||
Net cash used in operating activities |
(4,288,164 | ) | (2,681,396 | ) | ||||
CASH FLOWS FROM INVESTING ACTIVITIES |
||||||||
property, plant and equipment |
- | - | ||||||
Net cash used in investing activities |
- | - | ||||||
CASH FLOWS FROM FINANCING ACTIVITIES |
||||||||
Issuance of common shares, net |
- | - | ||||||
Issuance of preferred shares, net |
- | - | ||||||
Redemption of preferred shares |
(328,904 | ) | - | |||||
Exercise of warrants for cash |
- | 146,250 | ||||||
Federally guaranteed loans |
- | 499,900 | ||||||
Proceeds from (repayment to) convertible notes, net |
- | - | ||||||
Proceeds from (repayment to) convertible debentures, net |
- | 139,780 | ||||||
Issuance of shares from uplisting |
- | - | ||||||
Proceeds pursuant to term loan, net |
50,070 | - | ||||||
Preferred Stock Dividend |
(516,817 | ) | (204,842 | ) | ||||
Net cash provided by financing activities |
(795,651 | ) | 581,088 | |||||
Effect of foreign currency translation |
224,860 | 100,334 | ||||||
Net increase (decrease) in cash during the period |
(5,083,815 | ) | (1,999,974 | ) | ||||
Cash, beginning of period |
12,066,929 | 2,201,562 | ||||||
Cash, end of period |
7,207,974 | 201,588 | ||||||
| 截至2022年6月30日的三个月 | 截至2021年6月30日的三个月 | |||||||
| $ | $ | |||||||
经营活动的现金流 |
||||||||
净亏损 |
(4,776,252 | ) | (5,656,099 | ) | ||||
调整以调节净亏损与运营中使用的净现金 |
||||||||
基于股票的薪酬 |
149,190 | 155,851 | ||||||
为服务而发行股份 |
7,051 | - | ||||||
为服务发行认股权证 |
77,414 | 151,897 | ||||||
累加和摊销费用 |
- | 2,335,167 | ||||||
衍生负债的公允价值变动 |
198,224 | 298,983 | ||||||
债务损失 |
50,908 | 28,213 | ||||||
财产、厂房和设备折旧 |
1,488 | - | ||||||
经营性资产和负债变动情况： |
||||||||
应收账款净额 |
179,758 | (401,818 | ) | |||||
库存 |
(588,130 | ) | 92,694 | |||||
押金和其他应收款 |
(4,312 | ) | (86,221 | ) | ||||
应付账款和应计负债 |
416,047 | 399,937 | ||||||
用于经营活动的现金净额 |
(4,288,164 | ) | (2,681,396 | ) | ||||
投资活动产生的现金流 |
||||||||
财产、厂房和设备 |
- | - | ||||||
用于投资活动的现金净额 |
- | - | ||||||
融资活动产生的现金流 |
||||||||
普通股发行，净额 |
- | - | ||||||
发行优先股，净额 |
- | - | ||||||
优先股的赎回 |
(328,904 | ) | - | |||||
行使现金认股权证 |
- | 146,250 | ||||||
联邦担保贷款 |
- | 499,900 | ||||||
可转换票据收益(偿还)，净额 |
- | - | ||||||
可转换债券收益(偿还)，净额 |
- | 139,780 | ||||||
通过上市发行股票 |
- | - | ||||||
根据定期贷款获得的收益，净额 |
50,070 | - | ||||||
优先股分红 |
(516,817 | ) | (204,842 | ) | ||||
融资活动提供的现金净额 |
(795,651 | ) | 581,088 | |||||
外币折算的影响 |
224,860 | 100,334 | ||||||
期内现金净增(减)额 |
(5,083,815 | ) | (1,999,974 | ) | ||||
期初现金 |
12,066,929 | 2,201,562 | ||||||
期末现金 |
7,207,974 | 201,588 | ||||||
SOURCE: Biotricity, Inc.
资料来源：Biotricity，Inc.